ArticleScientific reports2025
Development and preliminary validation of a predictive model for IgA nephropathy progression.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Routine Laboratory Biomarkers for Survival Prediction After Limb-Salvage Surgery in Osteosarcoma: Development of a LASSO-Cox Prognostic Model and Internal Validation.Journal of clinical medicine · 2026Article
- IgA Nephropathy: Mechanisms, Risk Stratification, and Precision Therapy.Diagnostics (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
IgA nephropathy (IgAN), the most common primary glomerular disease worldwide, poses challenges in predicting progression at diagnosis-particularly in primary care. This study developed and validated a model to estimate 5-year renal survival and support early risk stratification for personalized management. A total of 1135 patients with biopsy-confirmed IgAN from Hangzhou Hospital of Traditional Chinese Medicine (2014-2017) were retrospectively enrolled and randomly assigned to training and internal validation cohorts in a 7:3 ratio. An external validation cohort comprising 352 patients was obtained from three independent centers (2015-2020). To identify robust prognostic variables, 1000 bootstrap samples were generated from the training set, each subjected to tenfold cross-validation to determine the optimal regularization parameter (λ) for the LASSO-Cox model. Variables with non-zero coefficients were recorded across iterations, and the five most frequently selected were used to construct both the XGBoost survival model and a corresponding nomogram. Model performance was evaluated through discrimination, calibration, and clinical utility using ROC curves, Brier scores, calibration curve and decision curve analysis. The area under the curve (AUC) of the nomogram was 0.951 (95% CI, 0.914-0.988) in the training cohort and 0.927 (95% CI, 0.877-0.978) in the internal validation cohort. In the external validation cohort, the AUC was 0.913 (95% CI, 0.870-0.955). The Brier scores were 0.029 and 0.045 for the internal and external validation cohorts, respectively. DCA further demonstrated the favorable clinical utility of the nomogram. A clinically practical prognostic model incorporating routine clinical and pathological features was developed to estimate 5-year renal survival in patients with IgAN. Specifically designed for primary care settings, the model leverages easily accessible data to enable early identification of high-risk individuals and support personalized long-term management. Its simplicity and applicability in resource-limited environments make it a valuable tool for improving outcomes beyond specialist centers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.